Press "esc" to clear
Go to Advanced Search
Showing results 5160 of 237

Article ID: 672472

Pre-Existing Immunity to Dengue and West Nile Viruses May Cause Increased Risk in Zika-Infected

Mount Sinai Health System

As the Zika virus continues to spread rapidly across the globe, it might pose a particular risk to people previously infected with two related viruses, dengue and West Nile, researchers at the Icahn School of Medicine at Mount Sinai have found. Their study, published in the journal Science, may help explain the severe manifestations of Zika virus infection observed in specific populations, including those in South America.

Released:
4-Apr-2017 5:05 PM EDT
basler_500x500-360x360.jpg

Article ID: 671054

Georgia State Researcher Gets $4.1 Million Federal Grant to Develop Drug to Combat Ebola Virus

Georgia State University

Dr. Christopher Basler, a professor in the Institute for Biomedical Sciences at Georgia State University, director of the university’s Center for Microbial Pathogenesis and a Georgia Research Alliance Eminent Scholar in Microbial Pathogenesis, has received a five-year, $4.1 million federal grant to develop a drug targeting Ebola virus.

Released:
13-Mar-2017 10:00 AM EDT
BiocontainmentPhoto.jpg

Article ID: 668825

Ebola Grant Expanded From $12 Million to $24 Million

University of Nebraska Medical Center (UNMC)

Supplemental funding will allow three partner institutions to perform additional site visits, conduct more education and training courses, as well as build a special pathogens research network.

Released:
3-Feb-2017 7:00 AM EST

Article ID: 666968

UF Plays Key Role in Trial for Successful Ebola Vaccine

University of Florida

An international group of researchers associated with the World Health Organization has published its final report on the Ebola vaccine trial in Guinea, finding that the vaccine is a safe and effective way to prevent Ebola infection.

Released:
23-Dec-2016 10:05 AM EST

Article ID: 666966

Trial Results Confirm Ebola Vaccine Provides High Protection Against Disease

University of Maryland School of Medicine

An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, according to a new study that included researchers from the University of Maryland School of Medicine.

Released:
23-Dec-2016 8:30 AM EST
CPIlogo.jpg

Article ID: 664515

Collaborations Pharmaceuticals, Inc. And Texas Biomed Announce NIH Award to Develop a Treatment for Ebola

Texas Biomedical Research Institute

The National Center for Advancing Translational Sciences (NCATS) recently awarded $596,533.00 to Collaborations Pharmaceuticals, Inc. (CPI) to initiate a partnership with Texas Biomedical Research Institute aimed at repurposing an antimalarial for use against the Ebola virus.

Released:
10-Nov-2016 8:00 AM EST
20161103Andersen_Grubaugh.jpg
  • Embargo expired:
    3-Nov-2016 12:00 PM EDT

Article ID: 664105

New TSRI Study Suggests Ebola Can Adapt to Better Target Human Cells

Scripps Research Institute

A new study co-led by scientists at The Scripps Research Institute (TSRI) suggests that Ebola virus gained a genetic mutation during the 2013–16 epidemic that appears to have helped it better target human cells.

Released:
2-Nov-2016 3:25 PM EDT
AnnaStewart_detail.jpg

Article ID: 661788

Sociol-Ecological System Approach Leads to New Information in Study of Mosquito-Borne Viruses

SUNY Upstate Medical University

In an article published online Sept. 13 in UGEC Viewpoints , Upstate Medical University researcher Anna Stewart Ibarra, PhD, MPA, describes how a collaborative approach by researchers of varying disciplines is being used as a framework for studying the mosquito-borne viruses, zika, dengue and chikungunya.

Released:
28-Sep-2016 2:05 PM EDT
  • Embargo expired:
    8-Sep-2016 2:00 PM EDT

Article ID: 660276

New ‘Trojan Horse’ Antibody Strategy Shows Promise Against All Ebola Viruses

Albert Einstein College of Medicine

In research published in Science, a team of scientists describe a new therapeutic strategy to target a hidden Achilles’ heel shared by all known types of Ebola virus. Two antibodies developed with this strategy blocked the invasion of human cells by all five ebolaviruses. The team included scientists from Albert Einstein College of Medicine, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Integrated Biotherapeutics, Vanderbilt University Medical Center, and The Scripps Research Institute.

Released:
6-Sep-2016 12:00 PM EDT
GP_ZMapp_5.jpg

Article ID: 658749

TSRI Scientists Pinpoint Ebola’s Weak Spots

Scripps Research Institute

Scientists at The Scripps Research Institute now have a high-resolution view of exactly how the experimental therapy ZMapp targets Ebola virus.

Released:
8-Aug-2016 4:05 PM EDT

Showing results 5160 of 237

Chat now!